Salvia officinalis, Rosmarinic and Caffeic Acids Attenuate Neuropathic Pain and Improve Function Recovery after Sciatic Nerve Chronic Constriction in Mice

Zineb El Gabbas, Kenza Bezza, Jawad Laadraoui, Mehdi Ait Laaradia, Aaziz Kebbou, Sara Oufquir, Abderrahman Boukhira, Rachida Aboufatima, and Abderrahman Chait

1Laboratory of Pharmacology, Neurobiology and Behavior, Semlalia Faculty of Sciences, Cadi Ayyad University, Marrakech, Morocco
2Biochemistry and Toxicology Department, Avicenna Military Hospital, Medical School Faculty, Cadi Ayyad University, Marrakech, Morocco
3Laboratory of Génie Biologique, Sultan Moulay Slimane University, Faculty of Sciences and Techniques, Beni Mellal, Morocco

Correspondence should be addressed to Zineb El Gabbas; elgabbas.zineb@gmail.com

Received 20 February 2019; Revised 22 April 2019; Accepted 29 May 2019; Published 24 June 2019

1. Introduction

Neuropathic pain is a chronic pain caused by injury of somatosensory neurons, which gives rise to pain symptoms that persist over time [1]. It is classified according to three features: the underlying disease, the site of lesion (i.e., a peripheral nerve lesion or spinal cord), and the underlying mechanism.

Generally, in neuropathic pain, the symptoms are frequently associated with abnormal sensations and may also be caused by stimuli that can be nonnociceptive (allodynia) or weakly nociceptive, with an amplified reaction (hyperalgesia) [2]. The pathogenesis of neuropathic pain is characterized by neuroinflammation induced activation of immune cells and increased production of several inflammatory mediators, predominantly tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-33 (IL-33) [3–5], which play an important part in the development of neuropathic pain [6–8]. In addition, epidemiological studies have reported a positive correlation between serum levels of TNF-α, C reactive protein (CRP), and erythrocyte sedimentation rate (ESR) in patients with neuropathy [9,10].
2. Materials and Methods

2.1. Animals. The experiments were performed using Swiss male mice between 24 and 29 g, bred in the central animal care facilities of Cadi Ayyad University, Marrakech, Morocco. Animals were housed (six per cage) under controlled temperature (20±2°C), humidity (60%), and lighting (12/12h light/dark cycle, dark from 7 P.M.), with free access to food and water. All the experimental protocols were carried out in accordance with the European Council Directive (EEC, 1986/609) and duly approved by the Council Committee of research laboratories of the Faculty of sciences, Cadi Ayyad University of Marrakech. All efforts were made to minimize animal suffering and to reduce the number of animals used.

2.2. Plant Material. The leaves of Salvia officinalis were collected from the Moroccan high Atlas Mountain (Ourika region), in February 2017, and were identified by Professor Ouhammou at the Faculty of Sciences Semlalia, University Cadi Ayyad Marrakech, Morocco. A voucher sample (MARK-10004) has been deposited at the herbarium of the faculty.

The leaves were dried in the shade at 40°C and ground into a fine powder.

2.3. Preparation of Ethanolic Extract. The powdered leaves of SO (200g) were extracted with ethanol (750 ml, 80% v/v) in a Soxhlet apparatus for 75h at 65°C. After extraction, the solvent was evaporated by a Rotavapor apparatus at 45°C. The final weight of the extract was 40.2 g.

2.4. Phytochemical Analysis of Ethanolic Extract of Salvia officinalis

2.4.1. Determination of Total Phenolic (TPC), Flavonoids (TFC), and Condensed Tannin Contents (TTC). The total phenolic content of SO ethanolic extract was assessed using Folin-Ciocalteu method [28]. 100 μl of the extract was diluted with 3.7 ml of distilled water, and 200 μl of Folin-Ciocalteu reagent was added. Thereafter, 5 min, 20% sodium carbonate (1 ml, Na2CO3) was added. The solution was agitated and incubated in dark for 45 min at 25°C. Then, absorbance was read at 725 nm a UV-Vis spectrophotometer (VR-2000, Spain). The total phenolic concentration of SO ethanolic extract is reported in terms of mg equivalent Gallic acid per g of the dry matter of extract (DM). All samples were carried out in triplicate.

The flavonoids content of SO extract was determined based on the aluminum trichloride method [29]. Aliquots (200 μl) of diluted extract were added to 5% NaNO2 solution (60 μl), followed by 10% AlCl3 (40 μl), and incubated for 6 min, followed by the addition of NaOH (400 μl). Then, distilled water (500 μl) was added. The absorbance of the solution was read at 510 nm. The TFC in SO was reported as mg equivalent catechin per g of the DM.

Tannins in SO extract are evaluated as follows [30]. Sample extract (300 μl) was added to a solution of vanillin (3 ml, 4% methanol) and HCl (1 ml). The absorbance was measured at 500nm. The results were reported as catechin per g of the extract.
2.4.2. In vitro Antioxidant Activity

**DPPH Assay.** The radical scavenging activity of SO sample was performed by the method of Burda and Oleszek [31]. 25 µl of the different sample or standard concentrations (butylated hydroxyl toluene (BHT) and Quercetin) was added to 2.8 ml of the methanol solution of DPPH (0.004%) and left to stand 60 min at room temperature. The absorbance was recorded at 517 nm. The measurements were carried out in triplicate. The antiradical activity of SO was evaluated as a percentage of DPPH discoloration (IC50 value).

**Reducing Power Assay (FRAP).** The FRAP assay of SO extract was realized according to the method of Oyaizu [32]. The plant (1 ml) was added to the sodium phosphate buffer solution (0.2 M; pH 6.6; 2.5 ml) and 1% of potassium ferricyanide (K3Fe (CN) 6; 2.5ml). After 20 min of incubation at 50°C the solution of Cl2C6COOH (2ml) was added and centrifuged (3000×g; 10min). Finally, a 2.5 ml aliquot of the mixture was combined with 0.5 ml ferric chloride (0.1%, FeCl3) and 2.5 of water.

Reading absorbance was set at 700 nm. BHT and Quercetin were used as a positive control.

**β-Carotene/Linoleic Acid Bleaching Method.** In this test, the antioxidant capacity of SO ethanolic extract is performed following the method of Kartal et al. [33]. β-carotene/linoleic acid emulsion was prepared by solubilization of 0.5 mg of β carotene in chloroform (1 ml); linoleic acid (25 µl); and 200 mg of Tween 20, then 100 ml of water was added to the solution. The emulsion (2.5 ml) was added to the extract solution (350 µl) or synthetic antioxidant reference (BHT). The absorbance of the prepared emulsion was measured at 470nm.

\[
% \text{Inhibition} = \left( \frac{A_{A(2h)} - A_{B(2h)}}{A_{B(0)} - A_{B(2h)}} \right) \times 100
\]

where \(A_{A(2h)}\) and \(A_{B(2h)}\) are the absorbances of the sample and control, respectively, after 2 h and \(A_{B(0)}\) is the absorbance of control t=0.

2.4.3. Determination of the Polyphenolic Content by HPLC. The high-performance liquid chromatography (Knauer) equipped with a (K-1001) pump and a PDA detector (200-700 UV-Vis) was used to separate and characterize phenolic compounds present in SO extract. The analysis was performed with a Eurospher II 100-5, column (4.6×250 mm) and the temperature was set at 25°C. The flow rate was 1 ml/min, the sample volume injected was 2ml, and the wavelengths of detection were set at 280 nm. Acidified water (A) and acetonitrile (B) mixture were used as the optimal mobile phase for a total running time of 60 min. The identification of phenolic compounds was made by comparison of retention time and spectra with those of commercially available standard compounds.

2.5. Induction of Neuropathic Pain by CCI. Neuropathy was induced in animals following the method of Bennett and Xie [34]. The mice were anesthetized by chloral hydrate (300 mg/Kg, i.p.). Then four loose ligatures (chronic gut 4-0, with 1 mm spacing) were tied around the left sciatic nerve. Sham-operated mice underwent the same surgical procedure except for the sciatic nerve ligation.

2.6. Drugs and Pharmacological Treatments. The following drugs were used: Clomipramine (5 mg/Kg) (Novartis, Maroc, S.A.), Rosmarinic acid 96%, and Caffeic acid purchased from Sigma-Aldrich (St. Louis, MO, USA) and Salvia officinalis ethanolic extract (100 and 200 mg/Kg). Drugs were dissolved in 0.9% NaCl solution before administration.

2.7. Experimental Design. Animals were assigned into the following 9 groups (\(n = 6\), for each group):

(i) Vehicle group: intact animals treated with normal saline (5 ml/Kg i.p.).

(ii) Sham group: mice which underwent the surgical procedure without nerve ligation and treated with normal saline (5 ml/kg i.p.).

(iii) SO group: animals which were treated with sage extract per se (100 and 200 mg/kg p.o.).

(iv) CLOM group: animals which received Clomipramine per se (5 mg/kg i.p.).

(v) ROS group: animals treated with Rosmarinic per se (10 and 20 mg/kg i.p.).

(vi) CAF group: animals treated with Caffeic acid per se (30 and 40 mg/kg i.p.).

(vii) CCI group: animals with chronic constriction of the sciatic nerve.

(viii) CCI+ SO group: CCI animals treated with sage extract per se (100 and 200 mg/kg p.o).

(ix) CCI+ ROS or CAF acid: CCI animals which received Rosmarinic (10 and 20 mg/kg i.p.) or Caffeic acid (30 and 40 mg/kg i.p.).

(x) CCI+ CLOM group: CCI animals treated with Clomipramine (5 mg/kg i.p.).

As outlined in Figure 1, the experimental protocol followed in this study was initiated (after surgery) by the measurement of baseline behavioral neuropathic pain tests for all tested animals. Mice were divided into 9 groups, and data were collected from six individual mice in each treatment group (\(n = 6\)). Then tests were done between 10h and 14h on the 1st day, 7, 14, and 21 after surgery and the behavioral parameters were measured at 40 minutes after chronic treatment with different drugs. At the end of 3 weeks of tests, biochemical, hematological, and histopathological analyses were evaluated.

**Pain Behavior Testing.** Neuropathic pain behavior tests were made up of four tests: mechanical, cold allodynia, thermal hyperalgesia, and sciatic nerve function (walking test).

2.7.1. Mechanical Allodynia (von Frey Test). In order to evaluate the sensory function of the sciatic nerve, paw withdrawal threshold in the response to mechanical stimuli was measured using von Frey test (Bioseb, USA); 10 filaments, with approximately equal logarithmic incremental bending
forces, were chosen [35]. The mice were placed in a plastic cage on a metal mesh floor and were allowed to get used to the environment prior to testing for 10 min. A series of von Frey filaments stimuli with an ascending order of forces, 0.04 g, 0.07 g, 0.16 g, 0.4 g, 0.6 g, 1 g, 1.4 g, 2 g, and 4 g, were applied vertically to the plantar surface of the hind paw. Each filament was tested five times per paw and the mechanical threshold was defined when the tested mice showed at least three withdrawals out of five consecutive trials.

2.7.2. Cold Allodynia (Acetone Test). For cold allodynia, paw withdrawal latency to cold stimulus was evaluated using the acetone spray test, in which 50 μL of acetone was applied to the plantar surface of mice left hind paw 5 times (at 5 min intervals). For 30 seconds, the mouse cold chemical sensitive reaction was recorded if the mouse lifted the hind paw. The duration of paw withdrawal was measured and expressed as cumulative reaction time [36].

2.7.3. Thermal Hyperalgesia (Hot-Plate Test). In the hot-plate test, the heat thermal sensitivity of the hind paw was assessed by using hot-plate apparatus (UgoBasil, Italy; Socrel DS-37). In this experiment, the animals were placed on the top of a preheated (52.5° ± 0.5°C) plate surface, and the time of paw withdrawal reaction was recorded (cut-off time was set at 20 s) [37].

2.7.4. Sciatic Nerve Function (SFI)-Walking Test. In this experiment, SFI was evaluated, as described by De Medinaceli [38], and based on the measurements recorded during walking tracks of tested animals [39].

Walking track analysis was performed on all mice one day before surgery and on days 1, 7, 14, and 21 following surgery. Prior to the injury, the mice were trained to traverse along a confined walkway 7.5 cm wide by 60 cm, covered with precut white paper, terminating in a cage similar to their home cage, with bedding. Footprints were obtained by dipping both hind paws in a nontoxic finger paint.

To evaluate the degree of the sciatic nerve function, three specific factors were calculated for each of the 3 print measurements and using the following formula [38]:

\[
SFI = -38.3 \left( \frac{EPL-NPL}{NPL} \right) + 109.5 \left( \frac{ETS-NTS}{NTS} \right) + 13.3 \left( \frac{EIT-NIT}{NIT} \right) - 8.8
\]

(2)

where N is normal, E is experimental, PL denotes print length, TS denotes total toe spreading, and IT denotes the distance from the second to the fourth toe.

The SFI was analyzed as SFI oscillating around 0 considered to reflect normal function; SFI= -100 indicates significant impairment.

2.8. Hematological and Biochemical Analysis. After 21 days of surgery and behavioral evaluation, blood samples were withdrawn from the orbital sinus of mice for the evaluation of hematological factors:

| Groups without CCI | Groups with CCI                        |
|---------------------|----------------------------------------|
| Vehicle and sham (normal saline 5ml/Kg p.o.) | CCI (normal saline 5ml/Kg p.o.)       |
| Sage extract (100 and 200 mg/kg p.o.) | CCI + Sage (100 and 200 mg/kg p.o.)   |
| Clomipramine (5mg/Kg i.p.) | CCI + Clomipramine (5mg/Kg i.p.)      |
| Rosmarinic (10 and 20 mg/kg i.p.) | CCI + Rosmarinic (10 and 20 mg/kg i.p.) |
| Caffeic acid (30 and 40 mg/kg i.p.) | CCI + Caffeic acid (30 and 40 mg/kg i.p.) |

Figure 1: Schematic timeline and experimental design used in this study. *Salvia officinalis* (SO), Rosmarinic acid (ROS), Caffeic acid (CAF), and Clomipramine (CLOM).
TABLE 1: Total phenolic compounds, total flavonoids compounds, and total tannins of Salvia officinalis ethanolic extract.

|                  | TPC (mg GAE/g DM) | TFC (QEeq/1 g DM) | TTC (CAT/g DM) |
|------------------|-------------------|-------------------|----------------|
| SO extract       | 120.30 ± 0.72      | 91.12 ± 0.50       | 22.10 ± 0.41   |

All determinations were carried out at least in triplicate and values were averaged and given along the standard error of the mean (mean ± SEM). Salvia officinalis (SO), TPC: total phenolic content; TFC: total flavonoid content; TTC: total tannin content.

TABLE 2: Antioxidant activity of Salvia officinalis ethanolic extract against DPPH, reducing power, and β-carotene methods.

|                  | Extract SO (IC50 mg/ml) | Quercetin (IC50 μg/ml) | BHT (IC50 μg/ml) |
|------------------|-------------------------|------------------------|-----------------|
| DPPH             | 0.66 ± 0.020             | 0.10 ± 0.002           | 0.35 ± 0.002    |
| Reducing power   | 0.22 ± 0.006             | 0.07 ± 0.001           | 0.12 ± 0.008    |
| β-carotene-linoleic acid | 0.30 ± 0.002                   | 2.62 ± 0.020          | 0.07 ± 0.001    |

Values are expressed as mg per ml and represent means of triplicate determination (mean ± SEM). Salvia officinalis (SO).

White blood cells (WBC), neutrophils (NEUT), eosinophils (EO), basophils (BASO), lymphocytes (LYMPH), and total monocytes (MONO). Red blood cell count (RBC), hemoglobin (Hb), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelets, and erythrocyte sedimentation rate (ESR) were determined using hematology automat XT-4000i.

Moreover, the biochemical assessment of serum CRP level was performed as a biomarker of inflammation.

2.9. Nephrotoxicity and Hepatotoxicity Analysis. Urea, Creatinine, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) were used as indicators of nephrotoxicity [40] and hepatotoxicity [41], respectively.

2.10. Histopathological Study. According to Sudoh et al. [42], sciatic nerve samples were fixed in 10% of formalin solution, transected (4 μm, thicknesses) and stained (Hematoxylin and Eosin). The qualitative analysis of nerve sections was done under a light microscope (450×) for axonal degeneration.

2.11. Statistical Analysis. All the results were expressed as the mean ± standard errors of mean (SEM). Comparison between different groups was made using the one-way analysis (ANOVA) and repeated measure model of ANOVA followed by Tukey’s post hoc test. A value of p<0.05 was considered to be statistically significant.

3. Results

3.1. Phytochemical Analysis of Ethanolic Extract of Salvia officinalis

3.1.1. Determination of Total Polyphenols, Flavonoids, and Condensed Tannins Contents Quantification. In the present study, the Salvia officinalis ethanolic extract shows a high level of phenolic compounds (120.30 ± 0.72 mg GAE/g DM), flavonoids (91.12 ± 0.50 mg QEeq/1 g DM), and condensed tannins (22.10 ± 0.41 mg CAT/g DM) (Table 1).

3.1.2. Antioxidant Activity. Table 2 presents the total antioxidant capacity obtained through the DPPH, reducing power and β-carotene assay for ethanolic extract of SO in comparison with that of Quercetin and of BHT (synthetic antioxidant). SO exhibited the best performance in reducing power systems and β-carotene/linoleic acid bleaching assay with IC50 values of 0.221 ± 0.006 mg/ml and 0.300 ± 0.002 mg/ml, respectively, whereas SO displayed a great antioxidant activity in DPPH free radical scavenging test system (IC50 = 0.661 ± 0.021 µg/ml).

3.1.3. Determination of the Polyphenolic Content by HPLC. HPLC chromatogram analysis indicates the presence of phenolic components in the SO extract namely the Rosmarinic acid as the major phenolic, Caffeic acid, p-coumaric acid, Quercetin, Gallic acid, Vanillic acid, Naringenin, Epicatechin, and Carnosic acid (Figure 2).

The concentrations of phenolic compounds identified in SO are tabulated in Table 3. The phenolic contents in the investigated extract ranged from to 13.64 mg 76.70 mg. Rosmarinic acid is the most abundant compound with the highest concentration (76.70 mg EGA/100 g DM), followed by Quercetin (28.23 mg EGA/100 g DM) and Vanillic acid (17.96 mg EGA/100 g DM).

3.2. Behavioral Tests. Sham animals were not statistically different from vehicle animals (data not shown). Animals that were treated for 21 days with SO extract per se (100 and 200 mg/kg), Rosmarinic (10 and 20 mg/kg) and Caffeic acids (30 and 40 mg/kg), and Clomipramine (5 mg/Kg) were also the same as sham animals regarding the behavioral parameters of neuropathic pain.

3.2.1. Effect of Salvia officinalis on Mechanical Allodynia Test. A series of von Frey filaments were used to assess the recovery of hypersensitivity to innocuous mechanical stimuli.

At 7, 14, 21 days after repeated oral treatment with SO (100 and 200 mg/kg, as a daily single dose for 21 days), the mechanical withdrawal thresholds in SO group were significantly higher than CCI group (p< 0.001). In addition,
3.2.2. Effect of Salvia officinalis on Cold Alloodynia (Acetone Test). From the 7th day after surgery, the results (Figure 4) indicate that the cold allosthenia induced by CCI was significantly attenuated by administration of SO in a dose-dependent manner (100 and 200 mg/kg, p.o.), (P < 0.05, vs. CCI group, Figure 4) as analyzed by one-way ANOVA followed by Tukey’s multiple comparison test. Rosmarinic acid (10 and 20 mg/kg) reduced hypersensitivity to cold stimulus on day 7 which continued up to day 21 (p < 0.001); the same effect was observed in animals treated with Clomipramine (5 mg/kg). Caffeic acid was also able to significantly decrease paw lifting response, but the most effective and promising effect was observed at the dose (40 mg/kg), (P < 0.001 vs. CCI group).

3.2.3. Effect of Salvia officinalis on Thermal Hyperalgesia (Hot-Plate Test). Twenty-one days following the CCI of the sciatic nerve, neuropathic pain was induced in all the animals, as evidenced by a significant decrease in hot-plate test latency (Figure 5). Following this, the effect of administration of SO, Rosmarinic, Caffeic acids, and Clomipramine (5 mg/kg) for 3 weeks on hot-plate latency was observed. Administration of SO (100 and 200 mg/kg) attenuated CCI-induced decrease in the nociceptive threshold for thermal hyperalgesia in a dose-dependent manner throughout the study duration after CCI induction, i.e., on days 14 and 21; this effect was highly significant as compared with the sham and CCI.

**Table 3: Quantification of main phenolic compounds in Salvia officinalis.**

| Phenolic compounds         | Concentrations (mg EGA/100 g DM) |
|----------------------------|-----------------------------------|
| Gallic acid                | 13.67                             |
| Caffeic acid               | 15.10                             |
| Carnosic acid             | 13.64                             |
| Vanillic acid             | 17.96                             |
| Naringeninin             | 15.84                             |
| Epicatechin                | 14.11                             |
| Rosmarinic acid           | 76.70                             |
| Quercetin                | 28.23                             |
| P-Coumaric acid           | 13.99                             |
Figure 3: Effect of the administration of **Salvia officinalis** (SO), Rosmarinic acid (ROS), Caffeic acid (CAF), and Clomipramine (CLOM), for 3 weeks, on paw withdrawal threshold CCI of the sciatic nerve in mice (n = 6). SO was orally given in doses of 100 mg/kg and 200 mg/kg. The data are expressed as mean ± SEM. ***p < 0.001 compared with sham group; +++p < 0.001 compared with CCI group.

Figure 4: Effect of the administration of **Salvia officinalis** (SO), Rosmarinic acid (ROS), Caffeic acid (CAF), and Clomipramine (CLOM), for 3 weeks, on the paw withdrawal duration (after the acetone drop test) following CCI of the sciatic nerve in mice (n = 6). SO was orally given in doses of 100 and 200 mg/kg. The data are expressed as mean ± SEM. **P < 0.001; *P < 0.05 compared with sham group; +++ P < 0.001 compared with CCI group.
3.2.4. Sciatic Nerve Function (SFI)-Walking Test. Chronic constriction injury of sciatic nerve resulted in significant development of sciatic functional loss as indicated by a decreased level of SFI when compared to the sham group (Figure 6). One day after surgery, there was no significant difference in SFI among groups (p > 0.05). Seven days after surgery, SFI was significantly reduced in the mice subjected to CCI (p < 0.05) vs. sham group. The administration of SO in a dose-dependent manner (100 and 200 mg/kg, p.o.) attenuated CCI-induced increase in the SFI value compared with the sham group (p < 0.001). Animals treated with Rosmarinic (10 and 20 mg/kg) or Caffeic acids (30 and 40 mg/kg) showed significant (p < 0.05) recovery in walking behavior at days 14 and 21 after CCI when compared with group sham group. Treatment of Clomipramine also produced similar effects over time after surgery.

3.3. Hematological and Biochemical Analysis. CCI induced hematologic variations in mice. For instance, we noted a decline in red blood cells (RBC) and Hb count and an upswing in platelets and ESR level (Tables 4 and 5), which were positively amended by SO extract and its major compounds (Rosmarinic and Caffeic acids), together with reference drug Clomipramine. The levels of WBC, neutrophils, basophils, lymphocytes, and total monocytes increased in the CCI group compared with the sham group (p > 0.05). However, a decrease was observed in the same parameters after the different treatments of CCI mice compared to the CCI group (p > 0.05). More so, high levels of serum CRP were observed in CCI animals. SO, its phenolic compounds (Rosmarinic and Caffeic acids), and Clomipramine significantly normalized serum CRP levels of CCI mice (Table 6).

3.4. Nephrotoxicity and Hepatotoxicity Analysis. As shown in Table 7 chronic treatment with SO (100 and 200 mg/kg, p.o.) and Rosmarinic (10 and 20 mg/kg) and Caffeic acids (30 and 40 mg/kg) had no significant effect on plasma levels (Urea, Creatinine, AST, and ALT).

3.5. Histopathological Study. Treatment with ethanolic extract of Salvia officinalis (100 and 200 mg/kg, p.o.) and Rosmarinic (10 and 20 mg/kg, i.p.) and Caffeic acids (30 and 40 mg/kg, i.p.) attenuated CCI-induced axonal degeneration and inflammatory changes. More so, CCI mice presented histological alteration as revealed by the marked proliferation of the inflammatory cell and decrease of degenerated fibers nerve fibers (Figure 7).
Table 4: Effect of administration of *Salvia officinalis* extract (SO), Rosmarinic (ROS) and Caffeic acids (CAF), and Clomipramine (CLOM), on hematological parameters in CCI mice. Red blood cells (RBC), hemoglobin (Hb), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelets, and erythrocyte sedimentation rate (ESR).

| Treatment        | RBC (x10^6/µL) | Hb (g/dL) | HCT (%) | MCV (fl) | MCH (pg) | MCHC (g/dL) | Platelets (x10^3/μL) | ESR (mm/1st h) |
|------------------|----------------|-----------|---------|----------|----------|-------------|----------------------|----------------|
| Sham             | 9.10±0.32      | 15.23±0.61| 31.66±1.22 | 54.36±0.79 | 15.35±0.16 | 30.60±0.70 | 53.50±4.19             | 3.46±0.04      |
| CCI              | 5.83±0.37      | 10.95±0.55 | 27.76±0.52 | 34.91±0.91 | 16.28±0.42 | 26.65±0.46 | 113.50±2.52            | 8.00±0.04      |
| CCI + SO 100     | 6.98±0.21      | 12.90±0.80 | 37.00±0.80 | 43.66±1.21 | 15.63±0.15 | 29.16±0.40 | 869.00±3.41            | 3.23±0.04      |
| CCI + SO 200     | 7.83±0.23      | 13.63±0.26 | 41.20±0.78 | 45.41±1.31 | 16.01±0.20 | 31.00±0.57 | 703.50±4.44            | 3.53±0.05      |
| CCI + ROS 10     | 8.10±0.21      | 13.40±0.40 | 40.41±0.55 | 46.06±0.92 | 15.30±0.29 | 30.33±0.42 | 675.00±1.23            | 3.58±0.03      |
| CCI + ROS 20     | 9.01±0.34      | 14.70±0.58 | 44.15±0.77 | 46.28±1.11 | 16.21±0.16 | 32.00±0.44 | 632.33±1.64            | 4.08±0.06      |
| CCI + CAF 30     | 7.76±0.27      | 13.08±0.46 | 39.25±0.79 | 45.65±1.33 | 15.40±0.21 | 29.33±0.33 | 71.66±3.87             | 4.2±0.03       |
| CCI + CAF 50     | 7.88±0.28      | 13.30±0.64 | 39.90±0.78 | 45.35±1.03 | 16.06±0.08 | 30.66±0.41 | 691.16±1.99            | 3.71±0.05      |
| CCI + ClOM 5     | 8.58±0.20      | 14.05±0.49 | 42.15±0.60 | 46.50±1.51 | 15.25±0.15 | 30.66±0.61 | 623.66±1.40            | 4.20±0.06      |

Results are expressed as mean ± SEM (n = 6), using one-way ANOVA followed by Tukey posttest. **p < 0.001 compared with sham group; ***p < 0.001 compared with CCI; *Salvia officinalis* (SO), Rosmarinic (ROS), Caffeic acids (CAF), and Clomipramine (CLOM).
Table 5: Effect of administration of *Salvia officinalis* extract (SO), Rosmarinic (ROS), Caffeic acids (CAF), and Clomipramine (CLOM), on hematological parameters in CCI mice. White blood cells (WBC), neutrophils (NEUT), eosinophils (EO), basophils (BASO), lymphocytes (LYMPH), and total monocytes (MONO).

| Treatment (mg/kg) | WBC (×10^3/µl) | NEUT (×10^3/µl) | EO (×10^3/µl) | BASO (×10^3/µl) | LYMPH (×10^3/µl) | MONO (×10^3/µl) |
|------------------|-----------------|-----------------|---------------|-----------------|------------------|-----------------|
| Sham             | 2.45±0.01       | 0.16±0.16       | 0.00±0.00     | 0.05±0.01       | 1.40±0.07        | 0.04±0.07       |
| CCI              | 2.56±0.03       | 0.19±0.19       | 0.00±0.00     | 0.21±0.12       | 1.86±0.21        | 0.22±0.13       |
| CCI + SO 100     | 1.83±0.16       | 0.00±0.00       | 0.00±0.00     | 0.07±0.04       | 2.45±0.07        | 0.14±0.08       |
| CCI + SO 200     | 2.72±0.13       | 0.00±0.00       | 0.00±0.00     | 0.07±0.04       | 1.42±0.06        | 0.04±0.07       |
| CCI + ROS 10     | 2.49±0.09       | 0.00±0.00       | 0.00±0.00     | 0.05±0.05       | 1.43±0.06        | 0.03±0.04       |
| CCI + ROS 20     | 2.55±0.07       | 0.00±0.00       | 0.00±0.00     | 0.05±0.01       | 1.42±0.04        | 0.03±0.03       |
| CCI + CAF 30     | 2.52±0.09       | 0.00±0.00       | 0.00±0.00     | 0.05±0.05       | 1.42±0.04        | 0.04±0.05       |
| CCI + CAF 40     | 2.48±0.10       | 0.00±0.00       | 0.00±0.00     | 0.05±0.05       | 1.44±0.02        | 0.04±0.05       |
| CCI + ClOM 5     | 2.56±0.05       | 0.00±0.00       | 0.00±0.00     | 0.06±0.03       | 1.36±0.01        | 0.05±0.07       |

Results are expressed as mean ± SEM (n = 6), using one-way ANOVA followed by Tukey posttest. p > 0.05. *Salvia officinalis* (SO), Rosmarinic (ROS), Caffeic acids (CAF), and Clomipramine (CLOM).
Table 6: Effect of administration of *Salvia officinalis* extract and major compounds (Rosmarinic and Caffeic acids) on biochemical parameter in CCI mice (C reactive protein (CRP)).

| Treatments (mg/kg) | Sham | CCI | CCI + SO 100 | CCI + SO 200 | CCI + ROS 10 | CCI + ROS 20 | CCI + CAF 30 | CCI + CAF 40 | CCI + CLOM 5 |
|-------------------|------|-----|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| CRP (mg/L)        | 5.6±0.2 | 38.0±0.3 | 12.0±0.3 | 15.0±0.3 | 13.5±0.2 | 15.3±0.3 | 12.7±0.1 | 17.1±0.3 | 11.6±0.2 |

Results are expressed as mean ± SEM (n = 6), using one-way ANOVA followed by Tukey posttest. * * * p < 0.001 with sham group; +++ p <0.001 compared with CCI. *Salvia officinalis* (SO), Rosmarinic (ROS), Caffeic acids (CAF), and Clomipramine (CLOM).
Table 7: Effect of administration of *Salvia officinalis* extract and major compounds (Rosmarinic and Caffeic acids) on biochemical parameters in CCI mice. Urea, Creatinine, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT).

| Treatments (mg/kg) | Sham | CCI | CCI + SO 100 | CCI + SO 200 | CCI + ROS 10 | CCI + ROS 20 | CCI + CAF 30 | CCI + CAF 40 | CCI + CLOM 5 |
|-------------------|------|-----|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| Urea (g/l)        | 0.20±0.01 | 0.20±0.01 | 0.20±0.02 | 0.30±0.02 | 0.20±0.01 | 0.30±0.01 | 0.20±0.02 | 0.30±0.02 | 0.30±0.01 |
| Creatinine (mg/l) | 1.40±0.10 | 1.30±0.00 | 1.50±0.10 | 1.40±0.05 | 1.50±0.10 | 1.50±0.10 | 1.50±0.10 | 1.60±0.10 | 1.60±0.10 |
| ALT (U/L)         | 48.20±1.40 | 51.70±1.40 | 55.00±0.90 | 50.30±1.10 | 54.30±1.10 | 52.40±1.30 | 49.80±0.90 | 49.00±0.90 | 50.00±0.90 |
| AST (U/L)         | 165.00±2.10 | 164.40±1.20 | 164.80±0.90 | 179.10±1.30 | 164.80±0.90 | 165.20±1.30 | 170.00±1.30 | 166.40±1.10 | 171.00±1.30 |

Results are expressed as mean ± SEM (n = 6), using one-way ANOVA followed by Tukey posttest. p > 0.05. *Salvia officinalis* (SO), Rosmarinic (ROS), Caffeic acids (CAF), and Clomipramine (CLOM).
Figure 6: Effect of the administration of *Salvia officinalis* (SO), Rosmarinic acid (ROS), Caffeic acid (CAF), and Clomipramine (CLOM), for 3 weeks on the sciatic functional index in the walking test, following CCI of the sciatic nerve in mice (n = 6). SO was orally given in doses of 100 and 200 mg/kg. The data are expressed as mean ± SEM. *p < 0.05 compared with sham group.

Figure 7: Effect of SO, Rosmarinic acid (ROS), Caffeic acids (CAF), and Clomipramine (CLOM) on sciatic nerve histopathological changes stained with H&E of CCI-induced neuropathy in male mice. Normal mice (vehicle) showed normal fiber arrangement (Blue arrow) and no inflammation. Sham-operated mice showed the same structure as observed in the normal mice; not any marked changes were observed. CCI induced widely separated nerve fibers (thin arrow) and changes in satellite and Schwann cells and showed an increase in the inflammatory cell infiltration (bold arrow). Pretreatment with SO, Rosmarinic and Caffeic acids, and Clomipramine increased axonal regeneration, slightly separated nerve fibers, and normalized the derangement observed in the CCI (H&E 400× and scale bar, 35 μm).

4. Discussion

Peripheral nerve injury like chronic constriction injury (CCI) is frequently used to screen the potential therapeutic agents against neuropathic pain in rodent [34, 43]. It can produce pain-related behaviors similar to those observed in human patients with neuropathy [36]. To the best of our knowledge, the present work is the first study assessing the beneficial effect of chronic treatment with *Salvia officinalis* extract and its major compounds (Rosmarinic and Caffeic acids) in CCI model under standardized experimental conditions. Parameters like mechanical hyperalgesia (von Frey test), paw cold allodynia (acetone test), paw thermal hyperalgesia (hot-plate test), and Sciatic nerve function index (SFI) were evaluated, respectively.
In this study, our data clearly demonstrated behavioral, biochemical (CRP), hematological, and histopathological alterations in CCI animals due to the induction of peripheral neuropathy in mice. These alterations started on the 3rd day after surgery and lasted throughout the experimental period. However, the chronic treatment with SO and Rosmarinic and Caffeic acids suppressed responses to pain behavior, when given daily in dose-dependent manner. The dosage range used during the experiments was tolerable and benign based on the toxicity profile [18, 44, 45]. In addition, the evaluation of nephrotoxicity and hepatotoxicity biomarkers revealed that the different chronic treatments used in this study did not alter Urea, Creatinine, AST, and ALT plasma levels. Therefore, SO and its major compounds seem to be safe regarding liver and renal damage.

The finding of our study showed that chronic administration of SO and its main bioactive components (Rosmarinic and Caffeic acids) significantly increased the sensitivity and reaction time to pain in irritable animals immediately 7 days after the induction of neuropathic pain and continued for 21 days. Many experimental studies provide evidence of the beneficial effects of SO on acute and chronic models of pain; they are in accordance with our results. It has been shown that hydroalcoholic extract of SO has anti-inflammatory and antinociceptive effects on chemical behavioral models [27, 46]. According to our phytochemical results, SO extract revealed a higher content of flavonoids and phenolic compounds such as Caffeic acid and Rosmarinic acid, which are known for their anti-inflammatory and analgesic activity [47]. Bauer et. al. reported [48] that SO compounds have analgesic effects via COX-2 selective inhibitors which have significant inhibitory effects on PGE2. Additionally, our results concerning the antineuropathic effect of Rosmarinic acid are in accordance with results reported by Rahbardar and his collaborator in CCI rats [8, 26]. In the existing hematologic variations, it is clear that a rise in ESR and a fall in Hb and RBC count in CCI animals represent inflammation condition [49], which was suppressed by the administration of all the treatments and standard drug for 21 days.

According to the literature and on the basis of our results, the alteration of RBC, Hb, and HCT levels in CCI animals reveals inflammatory anemia. This anemia (called also typically normocytic normochromic anemia) occurred in the setting of acute or chronic inflammation and it manifested by the decrease of RBC parameters. More so, the pathogenesis of neuropathic pain is characterized by neuroinflammation which could be responsible for the decreased RBC, Hb, and HCT parameters observed in our study. The treatment with *Salvia officinalis* and its major compounds increased the RBC level, which could be due to its anti-inflammatory effects [50, 51].

Changes were also observed in WBCs level. More so, the serum concentration of CRP (inflammatory biomarker) is produced as a prompt response to fluctuations in underlying inflammation [52], and CRP synthesis is mainly stimulated by proinflammatory cytokines, such as alpha tumor necrosis (TNF-α) [53]. The significantly low levels of serum CRP in CCI animals treated by SO, Rosmarinic and Caffeic acids, and Clomipramine as compared to CCI control mice indicate remission of inflammation. Lately, Rahbardar and his collaborators reported that Rosmarinic acid attenuates the symptoms of neuropathic pain by increasing the levels of TNF-α in CCI rats [8]. Moreover, a recent study demonstrates that Caffeic acid relieves neuropathic pain by decreasing the expression of proinflammatory cytokine tumor necrosis factor-α, IL-1β, and IL-6 [54]. So, the antineuropathic efficacy of *Salvia officinalis* (SO) and its phenolic derivative compounds (Rosmarinic and Caffeic acids) can be attributed to its inhibitory effects on the release of inflammatory mediators.

Interestingly, our results indicate that chronic treatment with SO mimic the effect of Clomipramine (TCA: tricyclic antidepressant) in mice with ligated sciatic nerve. This has only an antiallodynic effect in mechanical test and suppresses the hyperalgesic effect.

According to previous studies, tricyclic antidepressants are recommended as one of the first-line treatment in painful neuropathy [55]. Tricyclic antidepressants have a specific analgesic effect and exert their therapeutic effect by recruiting the endogenous opioid system. Their effect can be acutely blocked by a single injection of delta or kappa-opioid receptor antagonist which plays a crucial role in the inhibitory control of pain [56]. Chronic study of treatment with Clomipramine showed antihyperalgesic action in CCI rats and suggested in the implication of the opioid system [57]. However, SO extract (100 and 200 mg/kg) have been observed to have better pharmacotherapeutic effects in comparison to Clomipramine for management of CCI-induced neuropathic pain. Taken together, these data suggest that the endogenous opioid system plays a critical role in chronic TCA relief of neuropathic pain and could also be involved in the beneficial effect of SO extract in CCI model.

An important and new aspect of our study is that SO promotes the motor functional recovery of the injured sciatic nerve and axonal regeneration. This beneficial effect was further evidenced by higher SFI values in CCI mice treated with SO, Rosmarinic and Caffeic acids as well as histopathological analysis. On the basis of data in hand and with support from literature, it is suggested that the beneficial effect of SO and Rosmarinic and Caffeic acids on sciatic nerve regeneration could be attributed to its multiple pharmacological actions like antioxidative, anti-inflammatory, and neuroprotective properties. This has been demonstrated in the current results of this study, although other mechanisms may contribute to the observed neuroprotection. Further studies are needed to investigate the exact mechanism and possible protective effect of *Salvia officinalis* on other forms of neuronal injury.

## 5. Conclusion

In summary, this study demonstrates for the first time that continuous daily administration of SO and its major compounds attenuated neuropathic pain in the chronic constriction injury-induced behavioral changes in mice. Moreover, they possess neuroprotective effects as demonstrated in the results of the walking test. The present study suggests the potential use of *Salvia officinalis* in the treatment of...
neuropathic pain and the results corroborate the use of this plant in traditional medicine. However, further studies are necessary for the elucidation of its mechanisms of action.

Abbreviations

SO:  
Salvia officinalis
CCl:  
Chronic constriction injury
TPC:  
Total phenolic content
TFC:  
Total flavonoid content
TTC:  
Total tannin content
ROS:  
Rosmarinic acid
CAF:  
Caffeic acid
CLOM:  
Clomipramine
WBC:  
White blood cell
RBC:  
Red blood cell
Hb:  
Hemoglobin
ESR:  
Erythrocyte sedimentation rate
CRP:  
C reactive protein
AST:  
Aspartate transaminase
ALT:  
Alanine transaminase
TCAs:  
Clomipramine a tricyclic antidepressants
DPPH:  
2,2-Diphenyl-1-picrylhydrazyl
BHT:  
Butylated hydroxyltoluene
HPLC:  
High-performance liquid chromatography
SFI:  
Sciatic nerve function index

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors report no declarations of interest.

Acknowledgments

The authors would like to thank Mr. A. Regragui for providing animals, and we would also like to thank Mr. M.T. Kettani and Mrs. E Gaylard for the comments and language suggestion on the manuscript.

References

[1] T. S. Jensen, R. Baron, M. Haanpää et al., “A new definition of neuropathic pain,” PAIN, vol. 152, no. 10, pp. 2204–2205, 2011.
[2] A. Z. Burakgazi, W. Messersmith, D. Vaidya, P. Hauer, A. Hoke, and M. Polydelfis, “Longitudinal assessment of oxaliplatin-induced neuropathy,” Neurology, vol. 77, no. 10, pp. 980–986, 2011.
[3] J. Scholz and C. J. Woolf, “The neuropathic pain triad: neurons, immune cells and glia,” Nature Neuroscience, vol. 10, no. 11, pp. 1361–1368, 2007.
[4] N. Akimoto, K. Honda, D. Uta et al., “CCL-1 in the spinal cord contributes to neuropathic pain induced by nerve injury,” Cell Death & Disease, vol. 4, no. 6, pp. e679–e679, 2013.
[5] D. Schomburg, M. Ahmed, G. Miranpuri, J. Olson, and D. Resnick, “Neuropathic pain: role of inflammation, immune response, and ion channel activity in central injury mechanisms,” Annals of Neurosciences, vol. 19, pp. 125–132, 2012.
[6] N. N. Pathak, V. Balaganur, M. C. Lingaraju et al., “Anti-hyperalgesic and anti-inflammatory effects of atorvastatin in chronic constriction injury-induced neuropathic pain in rats,” Inflammation, vol. 36, no. 6, pp. 1468–1478, 2013.
[7] Y.-W. Chen, J.-I. Tzeng, K.-S. Liu, S.-H. Yu, C.-H. Hung, and J.-J. Wang, “Systemic diphenidol reduces neuropathic allodynia and TNF-alpha overexpression in rats after chronic constriction injury,” Neuroscience Letters, vol. 552, pp. 62–65, 2013.
[8] M. G. Rahbardi, A. Momin, S. Mehr, S. J. Mirnajafi-Zadeh, and H. Hosseinizadeh, “Rosmarinic acid attenuates development and existing pain in a rat model of neuropathic pain: An evidence of anti-oxidative and anti-inflammatory effects,” Phytomedicine, vol. 40, pp. 59–67, 2018.
[9] C. H. Park and S. H. Lee, “Investigation of high-sensitivity C-reactive protein and erythrocyte sedimentation rate in low back pain patients,” The Korean Journal of Pain, vol. 23, no. 2, pp. 147–150, 2010.
[10] T. Uher and P. Bob, “Neuropathic pain, depressive symptoms, and c-reactive protein in sciatica patients,” International Journal of Neuroscience, vol. 123, no. 3, pp. 204–208, 2012.
[11] N. Attal, G. Cruccu, R. Baron et al., “EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision,” European Journal of Neurology, vol. 17, no. 9, pp. 1113–1123, 2010.
[12] J. Lee and P. Nandi, “Improving the management of neuropathic pain,” The Practitioner, vol. 254, pp. 27–30, 2010.
[13] H. Singh, R. Arora, S. Arora, and B. Singh, “Ameliorative potential of alstonia scholaris (Linn.) R. Br. against chronic constriction injury-induced neuropathic pain in rats,” BMC Complementary and Alternative Medicine, vol. 17, no. 1, p. 63, 2017.
[14] A. K. Mehta and C. D. Tripathi, “Commiphora mukul attenuates peripheral neuropathic pain induced by chronic constriction injury of sciatic nerve in rats,” Nutritional Neuroscience, vol. 18, no. 3, pp. 97–102, 2015.
[15] J. Bellakhdar, La Pharmacopée Marocaine Traditionnelle. Médecine Arabe Ancienne et Savoirs Populaires, Ibis Press, Paris, pp. 764, 1997.
[16] E. Horváthová, A. Sranˇc´ıkov´a, E. Regendov´a-Sedl´aˇckov´ae tal., “Salvia officinalis flavonoid extracted,” Advanced Herbal Medicine, vol. 1, no. 3, pp. 31–41, 2015.
[17] S. Akhondzadeh, M. Noroozian, M. Mohammadi, S. Ohadinia, A. H. Jamshidi, and M. Khani, “Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomized and placebo-controlled trial,” Journal of Clinical Pharmacy and Therapeutics, vol. 28, no. 1, pp. 53–59, 2003.
[18] Z. El Gabbas, K. Bezza, J. Laadraoui, R. Makbal, R. Aboufata, and A. Chait, “Salvia officinalis induces antidepressant-like effect, anxiolytic activity and learning improvement in hippocampal lesioned and intact adult rats,” Bangladesh Journal of Pharmacology, vol. 13, no. 4, pp. 367–378, 2018.
[19] A. H. Mansourabadi, H. M. Sadeghi, N. Razavi, and E. Rezvani, “Anti-inflammatory and analgesic properties of salvinigenin, salvia officinalis flavonoid extracted,” Advanced Herbal Medicine, vol. 1, pp. 31–41, 2015.
[20] C. F. Lima, P. C. Valenato, P. B. Andrade, R. M. Seabra, M. Fernandes-Ferreira, and C. Pereira-Wilson, “Water and methanolic extracts of Salvia officinalis protect HepG2 cells
from t-BHP induced oxidative damage,” *Chemico-Biological Interactions*, vol. 167, no. 2, pp. 107–115, 2007.

[21] D. Hernández-Saavedra, I. F. Pérez-Ramírez, M. Ramos-Gómez, S. Mendoza-Díaz, G. Loarca-Piña, and R. Reynoso-Camacho, “Phytochemical characterization and effect of Calendula officinalis, Hypericum perforatum, and Salvia officinalis infusions on obesity-associated cardiovascular risk,” *Medicinal Chemistry Research*, vol. 25, no. 1, pp. 163–172, 2016.

[22] G. E. Bigford and G. Del Rossi, “Supplemental substances derived from foods as adjunctive therapeutic agents for treatment of neurodegenerative diseases and disorders,” *Advances in Nutrition*, vol. 5, no. 4, pp. 394–403, 2014.

[23] R. Lucarini, W. Bernardes, M. Tozatti et al., “Hepatoprotective effect of Rosmarinus officinalis and rosmarinic acid on acetaminophen-induced liver damage,” *Emirates Journal of Food and Agriculture*, vol. 26, no. 10, pp. 878–884, 2014.

[24] M. Tavafi, “Diabetic nephropathy and antioxidants,” *Journal of Nephropathology*, vol. 2, no. 1, pp. 20–27, 2013.

[25] F. Armutcu, S. Akyol, S. Ustunsoy, and F. F. Turan, “Therapeutic potential of caffeic acid phenethyl ester and its anti-inflammatory and immunomodulatory effects (Review),” *Experimental and Therapeutic Medicine*, vol. 9, no. 5, pp. 1582–1588, 2015.

[26] M. Ghasemzadeh Rahbardin, A. Momin, S. Mehri, S. J. Mirnajafi-Zadeh, and H. Hosseinizadeh, “Anti-inflammatory effects of ethanolic extract of Rosmarinus officinalis L. and rosmarinic acid in a rat model of neuropathic pain,” *Biomedicine & Pharmacotherapy*, vol. 86, pp. 441–449, 2017.

[27] A. N. A. Abad, M. H. K. Nouri, and F. Tavakkoli, “Effect of salvia officinalis hydroalcoholic extract on vincristine-induced neuropathy in mice,” *Chinese Journal of Natural Medicines*, vol. 9, pp. 354–358, 2011.

[28] V. L. Singleton and J. A. Rossi, “Colorimetry of total phenolics and phenolic acids from Foods with phosphomolybdic-phosphotungstic acid reagents,” *American Journal of Enology and Viticulture*, vol. 16, 1965.

[29] J. Zhiheng, T. Mengcheng, and W. Jianning, “The determination of flavonoid contents in mulberry and their scavenging effects on superoxide radicals,” *Food Chemistry*, vol. 64, no. 4, pp. 555–559, 1999.

[30] B. J. Xu and S. K. C. Chang, “A comparative study on phenolic profiles and antioxidant activities of legumes as affected by extraction solvents,” *Journal of Food Science*, vol. 72, no. 2, pp. S159–S166, 2007.

[31] S. Burda and W. Oleszek, “Antioxidant and antiaradical activities of flavonoids,” *Journal of Agricultural and Food Chemistry*, vol. 49, no. 6, pp. 2774–2779, 2001.

[32] M. Oyaizu, “Studies on products of browning reaction: antioxidative activity of products of browning reaction prepared from glucosamine,” *The Japanese Journal of Nutrition and Dietetics*, vol. 44, pp. 307–315, 1986.

[33] N. Kartal, M. Sokmen, B. Tepe, D. Daferera, M. Polissiou, and A. Sokmen, “Investigation of the antioxidant properties of *Ferula orientalis* L. using a suitable extraction procedure,” *Food Chemistry*, vol. 100, no. 2, pp. 584–589, 2007.

[34] G. J. Bennett and Y. H. Xie, “A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man,” *PAIN*, vol. 33, no. 1, pp. 87–107, 1988.

[35] M. R. Ghaseimzadeh, B. Amin, S. Mehri, S. J. Mirnajafi-Zadeh, and H. Hosseinizadeh, “Effect of alcoholic extract of aerial parts of Rosmarinus officinalis L. on pain, inflammation and apoptosis induced by chronic constriction injury (CCI) model of neuropathic pain in rats,” *Journal of Ethnopharmacology*, vol. 194, pp. 117–130, 2016.

[36] S. van der Wal, L. Cornelissen, M. Behet, M. Vaneker, M. Steegers, and K. Vissers, “Behavior of neuropathic pain in mice following chronic constriction injury comparing silk and catgut ligatures,” *SpringerPlus*, vol. 4, no. 1, p. 225, 2015.

[37] H. M. Shaheen, B. H. Ali, A. A. Alqarawi, and A. K. Bashir, “Effect of Psidium guajava leaves on some aspects of the central nervous system in mice,” *Phyotherapy Research*, vol. 14, pp. 107–111, 2000.

[38] L. de Medinaceli, W. J. Freed, and R. J. Wyatt, “An index of the functional condition of rat sciatic nerve based on measurements made from walking tracks,” *Experimental Neurology*, vol. 77, no. 3, pp. 634–643, 1982.

[39] M. Yamamoto, N. Okui, M. Tatebe, T. Shinhoara, and H. Hirata, “Regeneration of the perineurium after microsurgical resection examined with immunolabeling for tenascin-C and alpha smooth muscle actin,” *Journal of Anatomy*, vol. 218, no. 4, pp. 413–425, 2011.

[40] S. S. Mizokami, N. S. Arakawa, S. R. Ambrosio et al., “Kaurenic acid from *Sphagnetocilia trilobata* inhibits inflammatory pain: effect on cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway,” *Journal of Natural Products*, vol. 75, no. 5, pp. 896–904, 2012.

[41] J. Sereno, P. Rodrigues-Santos, H. Vala et al., “Transition from cyclosporine-induced renal dysfunction to nephrotoxicity in an in vivo rat model,” *International Journal of Molecular Sciences*, vol. 15, no. 5, pp. 8979–8997, 2014.

[42] Y. Sudo, S. Desai, A. Haderer et al., “Neurologic and histopathologic evaluation after high-volume intrathecal amitriptyline,” *Regional Anesthesia and Pain Medicine*, vol. 29, no. 5, pp. 434–440, 2004.

[43] A. S. Jagg, V. Jain, and N. Singh, “Animal models of neuropathic pain,” *Fundamental & Clinical Pharmacology*, vol. 25, no. 1, pp. 1–28, 2011.

[44] S. Kianbakht, B. Abasi, M. Perham, and F. Hashem Dadaghian, “Antihyperlipidemic effects of *Salvia officinalis* L. leaf extract in patients with hyperlipidemia: a randomized double-blind placebo-controlled clinical trial,” *Phytotherapy Research*, vol. 25, no. 12, pp. 1849–1853, 2011.

[45] M. R. Rodrigues, L. K. Kanazawa, T. L. das Neves et al., “Antinoceptive and anti-inflammatory potential of extract and isolated compounds from the leaves of *Salvia officinalis* in mice,” *Journal of Ethnopharmacology*, vol. 139, no. 2, pp. 519–526, 2012.

[46] S. Schröder, K. Beckmann, G. Franchini et al., “Can medical herbs stimulate regeneration or neuroprotection and treat neuropathic pain in chemotherapy-induced peripheral neuropathy?” *Evidence-Based Complementary and Alternative Medicine*, vol. 2013, Article ID 423713, 18 pages, 2013.

[47] D. Baricevic, S. Sosa, R. Della Loggia et al., “Topical anti-inflammatory activity of *Salvia officinalis* L. leaves: the relevance of ursolic acid,” *Journal of Ethnopharmacology*, vol. 75, no. 2–3, pp. 125–132, 2001.

[48] J. Bauer, S. Kuehnl, J. M. Rollinger et al., “Carnosol and carnosic acids from *Salvia officinalis* inhibit microsomal prostaglandin E2 synthase-1,” *The Journal of Pharmacology and Experimental Therapeutics*, vol. 342, no. 1, pp. 169–176, 2012.

[49] A. M. Uttra, S. J. Alameger, M. Shahzad, A. Shabbir, and S. Jahan, “Ephedra germadina aqueous ethanolic extract and fractions attenuate Freund Complete Adjuvant induced arthritis in...
Sprague Dawley rats by downregulating PGE2, COX2, IL-1β, IL-6, TNF-α, NF-kB and upregulating IL-4 and IL-10," *Journal of Ethnopharmacology*, vol. 224, pp. 482–496, 2018.

[50] P. G. Fraenkel, "Anemia of inflammation: a review," *Medical Clinics of North America*, vol. 101, no. 2, pp. 285–296, 2017.

[51] E. Nemeth and T. Ganz, "Anemia of inflammation," *Hematology/Oncology Clinics of North America*, vol. 28, no. 4, pp. 671–681, 2014.

[52] K. Samuel, A. George, and J. Boampong, "Antiarthritic effect of aqueous and ethanolic leaf extracts of pistia stratiotes in adjuvant-induced arthritis in sprague-dawley rats," *Journal of Experimental Pharmacology*, vol. 4, pp. 41–51, 2012.

[53] D. Zhang, M. Sun, D. Samols, and I. Kushner, "STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6," *The Journal of Biological Chemistry*, vol. 271, no. 16, pp. 9503–9509, 1996.

[54] H. Cheng, Y. Zhang, W. Lu, X. Gao, C. Xu, and H. Bao, "Caffeic acid phenethyl ester attenuates neuropathic pain by suppressing the p38/NF-κB signal pathway in microglia," *Journal of Pain Research*, vol. 11, pp. 2709–2719, 2018.

[55] A. Mohammed, "Studies of analgesic and anti-inflammatory effects of aqueous extract of ganoderma lucidum in mice and wister rats," *IOSR Journal of Pharmacy and Biological Sciences*, vol. 4, no. 4, pp. 54–57, 2012.

[56] I. Yalcin, N. Choucair-Jaafar, M. Benbouzid et al., "β2 adrenoceptors are critical for antidepressant treatment of neuropathic pain," *Annals of Neurology*, vol. 65, no. 2, pp. 218–225, 2009.

[57] A.-S. Wattiez, F. Libert, A.-M. Privat et al., "Evidence for a differential opioidergic involvement in the analgesic effect of antidepressants: prediction for efficacy in animal models of neuropathic pain?" *British Journal of Pharmacology*, vol. 163, no. 4, pp. 792–803, 2011.